Veracyte (VCYT) versus Digiliti Money Group (DGLT) Head-To-Head Review
Veracyte (NASDAQ: VCYT) and Digiliti Money Group (OTCMKTS:DGLT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.
Earnings and Valuation
This table compares Veracyte and Digiliti Money Group’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Veracyte||$65.08 million||3.29||-$31.35 million||($0.81)||-7.77|
|Digiliti Money Group||$7.97 million||0.20||-$15.16 million||N/A||N/A|
Insider and Institutional Ownership
69.2% of Veracyte shares are held by institutional investors. Comparatively, 11.3% of Digiliti Money Group shares are held by institutional investors. 13.4% of Veracyte shares are held by company insiders. Comparatively, 50.9% of Digiliti Money Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a summary of current recommendations and price targets for Veracyte and Digiliti Money Group, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Digiliti Money Group||0||0||1||0||3.00|
Veracyte currently has a consensus target price of $12.50, suggesting a potential upside of 98.73%. Digiliti Money Group has a consensus target price of $6.00, suggesting a potential upside of 3,650.00%. Given Digiliti Money Group’s stronger consensus rating and higher possible upside, analysts plainly believe Digiliti Money Group is more favorable than Veracyte.
Risk & Volatility
Veracyte has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500. Comparatively, Digiliti Money Group has a beta of -0.66, indicating that its stock price is 166% less volatile than the S&P 500.
This table compares Veracyte and Digiliti Money Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Digiliti Money Group||-147.73%||N/A||-199.21%|
Veracyte beats Digiliti Money Group on 7 of the 12 factors compared between the two stocks.
Veracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.
About Digiliti Money Group
Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.
Receive News & Stock Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related stocks with our FREE daily email newsletter.